Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers
Asymptomatic carriers contribute to the spread of Coronavirus Disease 2019 (COVID-19), but their clinical characteristics, viral kinetics, and antibody responses remain unclear. A total of 56 COVID-19 patients without symptoms at admission and 19 age-matched symptomatic patients were enrolled. RNA o...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.595773/full |
| _version_ | 1818676843016880128 |
|---|---|
| author | Tongyang Xiao Yanrong Wang Jing Yuan Haocheng Ye Lanlan Wei Xuejiao Liao Haiyan Wang Shen Qian Zhaoqin Wang Lei Liu Lei Liu Zheng Zhang Zheng Zhang Zheng Zhang |
| author_facet | Tongyang Xiao Yanrong Wang Jing Yuan Haocheng Ye Lanlan Wei Xuejiao Liao Haiyan Wang Shen Qian Zhaoqin Wang Lei Liu Lei Liu Zheng Zhang Zheng Zhang Zheng Zhang |
| author_sort | Tongyang Xiao |
| collection | DOAJ |
| description | Asymptomatic carriers contribute to the spread of Coronavirus Disease 2019 (COVID-19), but their clinical characteristics, viral kinetics, and antibody responses remain unclear. A total of 56 COVID-19 patients without symptoms at admission and 19 age-matched symptomatic patients were enrolled. RNA of SARS-CoV-2 was tested using transcriptase quantitative PCR, and the total antibodies (Ab), IgG, IgA, and IgM against the SARS-CoV-2 were tested using Chemiluminescence Microparticle Immuno Assay. Among 56 patients without symptoms at admission, 33 cases displayed symptoms and 23 remained asymptomatic throughout the follow-up period. 43.8% of the asymptomatic carriers were children and none of the asymptomatic cases had recognizable changes in C-reactive protein or interleukin-6, except one 64-year-old patient. The initial threshold cycle value of nasopharyngeal SARS-CoV-2 in asymptomatic carriers was similar to that in pre-symptomatic and symptomatic patients, but the positive viral nucleic acid detection period of asymptomatic carriers (9.63 days) was shorter than pre-symptomatic patients (13.6 days). There were no obvious differences in the seropositive conversion rate of total Ab, IgG, and IgA among the three groups, though the rates of IgM varied largely. The average peak IgG and IgM COI of asymptomatic cases was 3.5 and 0.8, respectively, which is also lower than those in symptomatic patients with peaked IgG and IgM COI of 4.5 and 2.4 (p < 0.05). Young COVID-19 patients seem to be asymptomatic cases with early clearance of SARS-CoV-2 and low levels of IgM generation but high total Ab, IgG, and IgA. Our findings provide empirical information for viral clearance and antibody kinetics of asymptomatic COVID-19 patients. |
| first_indexed | 2024-12-17T08:49:55Z |
| format | Article |
| id | doaj.art-b74a7eacfd594925b7df04e41e8920df |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-17T08:49:55Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-b74a7eacfd594925b7df04e41e8920df2022-12-21T21:56:06ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-03-01810.3389/fmed.2021.595773595773Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic CarriersTongyang Xiao0Yanrong Wang1Jing Yuan2Haocheng Ye3Lanlan Wei4Xuejiao Liao5Haiyan Wang6Shen Qian7Zhaoqin Wang8Lei Liu9Lei Liu10Zheng Zhang11Zheng Zhang12Zheng Zhang13National Clinical Research Center for Infectious Disease, School of Medicine, Institute of Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, ChinaDepartment of Pediatrics, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, ChinaDepartment of Infectious Diseases, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, ChinaNational Clinical Research Center for Infectious Disease, School of Medicine, Institute of Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, ChinaNational Clinical Research Center for Infectious Disease, School of Medicine, Institute of Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, ChinaNational Clinical Research Center for Infectious Disease, School of Medicine, Institute of Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, ChinaNational Clinical Research Center for Infectious Disease, School of Medicine, Institute of Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, ChinaNational Clinical Research Center for Infectious Disease, School of Medicine, Institute of Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, ChinaNational Clinical Research Center for Infectious Disease, School of Medicine, Institute of Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, ChinaNational Clinical Research Center for Infectious Disease, School of Medicine, Institute of Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, ChinaShenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, ChinaNational Clinical Research Center for Infectious Disease, School of Medicine, Institute of Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, ChinaShenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, ChinaGuangdong Key Laboratory for Anti-infection Drug Quality Evaluation, Shenzhen, ChinaAsymptomatic carriers contribute to the spread of Coronavirus Disease 2019 (COVID-19), but their clinical characteristics, viral kinetics, and antibody responses remain unclear. A total of 56 COVID-19 patients without symptoms at admission and 19 age-matched symptomatic patients were enrolled. RNA of SARS-CoV-2 was tested using transcriptase quantitative PCR, and the total antibodies (Ab), IgG, IgA, and IgM against the SARS-CoV-2 were tested using Chemiluminescence Microparticle Immuno Assay. Among 56 patients without symptoms at admission, 33 cases displayed symptoms and 23 remained asymptomatic throughout the follow-up period. 43.8% of the asymptomatic carriers were children and none of the asymptomatic cases had recognizable changes in C-reactive protein or interleukin-6, except one 64-year-old patient. The initial threshold cycle value of nasopharyngeal SARS-CoV-2 in asymptomatic carriers was similar to that in pre-symptomatic and symptomatic patients, but the positive viral nucleic acid detection period of asymptomatic carriers (9.63 days) was shorter than pre-symptomatic patients (13.6 days). There were no obvious differences in the seropositive conversion rate of total Ab, IgG, and IgA among the three groups, though the rates of IgM varied largely. The average peak IgG and IgM COI of asymptomatic cases was 3.5 and 0.8, respectively, which is also lower than those in symptomatic patients with peaked IgG and IgM COI of 4.5 and 2.4 (p < 0.05). Young COVID-19 patients seem to be asymptomatic cases with early clearance of SARS-CoV-2 and low levels of IgM generation but high total Ab, IgG, and IgA. Our findings provide empirical information for viral clearance and antibody kinetics of asymptomatic COVID-19 patients.https://www.frontiersin.org/articles/10.3389/fmed.2021.595773/fullasymptomaticviral clearanceantibodySARS-CoV-2COVID-19 |
| spellingShingle | Tongyang Xiao Yanrong Wang Jing Yuan Haocheng Ye Lanlan Wei Xuejiao Liao Haiyan Wang Shen Qian Zhaoqin Wang Lei Liu Lei Liu Zheng Zhang Zheng Zhang Zheng Zhang Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers Frontiers in Medicine asymptomatic viral clearance antibody SARS-CoV-2 COVID-19 |
| title | Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers |
| title_full | Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers |
| title_fullStr | Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers |
| title_full_unstemmed | Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers |
| title_short | Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers |
| title_sort | early viral clearance and antibody kinetics of covid 19 among asymptomatic carriers |
| topic | asymptomatic viral clearance antibody SARS-CoV-2 COVID-19 |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2021.595773/full |
| work_keys_str_mv | AT tongyangxiao earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers AT yanrongwang earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers AT jingyuan earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers AT haochengye earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers AT lanlanwei earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers AT xuejiaoliao earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers AT haiyanwang earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers AT shenqian earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers AT zhaoqinwang earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers AT leiliu earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers AT leiliu earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers AT zhengzhang earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers AT zhengzhang earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers AT zhengzhang earlyviralclearanceandantibodykineticsofcovid19amongasymptomaticcarriers |